LBOVI-A-1.

Background/aims: Treatment history may impact perceived effectiveness of antimuscarinic therapy for overactive bladder (OAB). This analysis of the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin (MATRIX) compares quality of life (QOL) in treatment-experienced vs -naive patients.Methods: MATRIX, an open-label, multicenter prospective trial, evaluated adults with OAB treated with transdermal oxybutynin 3.9 mg/d (Oxytrol®, Watson Pharma, Corona, CA) for ≤6 mos. Study population included 3 predefined patient groups: treatment naive (n=973), recently discontinued (therapy stopped 0-29 days prior; n=785), lapsed (no therapy ≥30 days; n=566). King's Health Questionnaire® (KHQ) was used to evaluate QOL. P values based on ANCOVA.Results: MATRIX enrolled 2878 patients (mean age 62.5y±14.8y; 87% women). At baseline, 46% had OAB symptoms ≥4y; 57% had prior oral OAB treatment (32% of whom with multiple drugs), predominantly extended-release tolterodine or oxybutynin. Baseline differences in impairment were seen between groups (P<.0001) in 5 of 10 KHQ domains (trend for increasing severity: naive < recently discontinued < lapsed). At study end, all KHQ domains except general health perception showed significant improvement (P<.0001). Magnitude of response was similar between groups in 6 domains, with greater improvement among lapsed and naive patients in 4 domains.Conclusions: OAB patients benefit from transdermal oxybutynin, regardless of treatment history.Clinical Pharmacology & Therapeutics (2005) 79, P82–P82; doi: 10.1016/j.clpt.2005.12.293 [ABSTRACT FROM AUTHOR]